Imperial Acquires TJP's Nicotine Pouches for US Market

Business by 2FIRSTS.ai
Jun.27.2023
Imperial Acquires TJP's Nicotine Pouches for US Market
Recently, Imperial Tobacco Group (ITG) announced the acquisition of TJP Lab's nicotine pouch business for £65 million, aiming to enter the US oral tobacco market.

Imperial Tobacco Group (ITG) announced on its official website that it has acquired the nicotine pouch business of Canada's TJP Laboratory for a price of £65 million. This move is aimed at expanding its presence in the US oral tobacco market.

 

After the completion of the acquisition, ITG has decided to reintroduce the series of products, totaling 14, under a completely new brand in the United States by the year 2024. Meanwhile, TJP will continue to manufacture nicotine pouches for ITG as per their contractual agreement.

 

Kim Reed, President and CEO of ITG, stated, "This presents us with an opportunity to expand our business in the United States with next-generation products, allowing us to offer a wider range of choices to legal adult consumers. We are looking forward to a long and successful partnership with TJP Laboratory.

 

David Richmond-Peck, CEO of TJP Laboratory, expressed in an interview the company's excitement about building a strong and lasting partnership with Empire, which has proven expertise in brand development, marketing, and sales execution in the United States. Empire has a long-standing track record of responsible operations on a global scale. This deal aligns with TJP Laboratory's commitment to developing and manufacturing products that promote global injury reduction, consumer choice, and flexibility.

 

It is reported that ITG has been promoting modern oral products in certain European markets under the brand names Zone X and Skruf.

 

References:

 

Imperial has recently announced the acquisition of the nicotine pouches range from TJP based in the United States.

 

This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

FDA nicotine pouch review delay report knocks tobacco shares lower
FDA nicotine pouch review delay report knocks tobacco shares lower
After Reuters reported before the market open that FDA reviews of nicotine pouch applications could face delays, shares of Philip Morris International, Turning Point Brands and British American Tobacco fell on April 1, underscoring the direct impact of U.S. regulatory signals on major tobacco companies and nicotine pouch expectations.
Apr.02
New Movement Emerges on EU Tobacco Excise Directive as Cyprus Tables Compromise Draft
New Movement Emerges on EU Tobacco Excise Directive as Cyprus Tables Compromise Draft
The long-stalled debate over the European Union’s Tobacco Excise Directive may be moving forward, with Cyprus, as holder of the EU Council presidency, putting forward a compromise draft. The reported proposal includes lowering the minimum excise duty requirement and granting a transitional period, with the aim of reaching political agreement by June 2026. The revision also covers e-cigarettes, heated tobacco, nicotine pouches and stronger controls on raw tobacco.
Apr.21 by 2FIRSTS.ai
Jinjia Shares Discloses 2025 Annual and Q1 2026 Results With Revenue Growth, Profit Pressure and Expanding New Tobacco Business
Jinjia Shares Discloses 2025 Annual and Q1 2026 Results With Revenue Growth, Profit Pressure and Expanding New Tobacco Business
Jinjia Shares’ 2025 annual report summary and first-quarter 2026 report show that the company recorded 2025 revenue of RMB 2.988 billion, up 4.57% year on year, while net profit attributable to shareholders turned to a loss of RMB 346 million. In the first quarter of 2026, revenue rose 58.13% year on year to RMB 1.005 billion, but attributable net profit fell 45.16% to RMB 36.5349 million. The company said both revenue and cost growth were related to the expansion of its new tobacco business.
Apr.28 by 2FIRSTS.ai
Ispire and Jincheng Pharma Form Joint Venture to Enter Global High-Growth Nicotine Pouch Market
Ispire and Jincheng Pharma Form Joint Venture to Enter Global High-Growth Nicotine Pouch Market
Summary Ispire Technology announced a strategic joint venture with Chinese pharmaceutical company Jincheng Pharma to manufacture and commercialize nicotine pouch products. The partnership combines pharmaceutical-grade production capabilities with Ispire’s global regulatory infrastructure and distribution network as the company expands beyond vaping hardware into oral nicotine products.
Business
May.13
Philippines Draft Order Would Bring Nicotine Pouches Under PS Licensing Scheme
Philippines Draft Order Would Bring Nicotine Pouches Under PS Licensing Scheme
The Philippine Department of Trade and Industry is planning to impose mandatory product certification on nicotine pouches in an effort to curb illicit nicotine product trade.
Apr.13 by 2FIRSTS.ai
Russian Duma Speaker Says Amendment Giving Regions Power to Ban Vape Sales Is Planned for Adoption in May
Russian Duma Speaker Says Amendment Giving Regions Power to Ban Vape Sales Is Planned for Adoption in May
Russian State Duma Speaker Vyacheslav Volodin said an amendment that would give Russian regions the power to ban vape sales is planned for adoption in May. Volodin said the decision concerns the health of citizens, especially children. He also said doctors have recorded a 30% increase in patients with respiratory diseases caused or aggravated by vape use, with adolescents and people under 35 most often affected.
Apr.24 by 2FIRSTS.ai